when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

LILLY · news · pharmadog

← back to LILLY

News mentioning LILLY

793 stories

Jul 16, 26STAT+: FDA approves Merck’s oral PCSK9 drug, a firststat

Jul 16, 26Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunobiospace

Jul 16, 26STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalsstat

Jul 16, 26STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckleystat

Jul 16, 26Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckleyendpoints

Jul 16, 26Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drugraps

Jul 15, 26STAT+: Bipartisan lawmakers want to require U.S. to probe reliance on foreign-made drugs, ingredientsstat

Jul 15, 26Eli Lilly invests in Oura to support patients on GLP-1 drugsendpoints

Jul 15, 26STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with statesstat

Jul 15, 26J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsbiopharma dive

Jul 15, 26STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and morestat

Jul 14, 26STAT+: FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded accessstat

Jul 14, 26STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last yearstat

Jul 14, 26Majority of new Ebola cases in eastern Congo are from unknown chains, as outbreak outpaces responsestat

Jul 14, 26STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and morestat

Jul 14, 26Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsbiopharma dive

Jul 11, 26Deals, deals, deals; Biohaven takes on Eli Lilly; and moreendpoints

Jul 10, 26STAT+: Roche ends Huntington’s gene-silencing programsstat

Jul 10, 26STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and morestat

Jul 9, 26Whistleblower takes on health insurance and FDA commissioner candidatesstat

Jul 9, 26Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing downendpoints

Jul 9, 26STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and morestat

Jul 9, 26Opinion: Who benefits from classifying obesity as a disease?stat

Jul 8, 26Biohaven looks to take on Lilly in the muscle-sparing obesity spaceendpoints

Jul 8, 26STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and morestat

Jul 7, 26Tampa General kicks off legal fight over Lilly's 340B restrictionsendpoints

Jul 7, 26Oberland pours up to $400M into MeiraGTx eye gene therapiesbiopharma dive

Jul 7, 26Kailera says obesity pill succeeds in late-stage trial in Chinabiopharma dive

Jul 7, 26STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and morestat

Jul 6, 26Gene editing developer Scribe plots an IPObiopharma dive

← prevpage 20 of 27next →